The GYG2 Knockout HeLa Polyclonal Cells product is a CRISPR/Cas9-edited polyclonal HeLa cell population with targeted disruption of the GYG2 gene. This heterogeneous knockout model enables functional analysis of glycogenin-2 without clonal selection biases, providing a biologically relevant population for studying glycogen metabolism and cancer biology. The polyclonal format reduces the impact of off-target effects and represents a comprehensive loss-of-function tool for interrogating the role of GYG2 in diverse cellular contexts.
Derived from a human cervical adenocarcinoma, HeLa cells are an HPV18-positive adherent epithelial cell line widely employed in cancer research, virology, and gene function studies. Their robust proliferation, ease of genetic manipulation, and well-characterized signaling networks establish them as a versatile platform for investigating metabolic pathways. Notably, the HeLa background exhibits a high glycolytic rate and active glycogen turnover, making it particularly suited for exploring the role of glycogenin-2 in tumor metabolic reprogramming and energy homeostasis.
GYG2 encodes glycogenin-2, a glycosyltransferase that initiates glycogen synthesis via autoglucosylation, generating a short ??-1,4-linked glucose primer for glycogen synthase (GYS1). Following insulin stimulation, the INSR/IRS1/PI3K/AKT signaling cascade phosphorylates and inhibits GSK3??, relieving inhibitory phosphorylation on GYS1. Concurrently, protein phosphatase 1 regulatory subunit PPP1R3C dephosphorylates and activates GYS1, which elongates the primer. Glycogen branching enzyme (GBE1) then introduces ??-1,6 branches to form mature glycogen particles. GYG2 physically interacts with GYS1 and PPP1R3C, and its activity is modulated by AMPK under energy stress. Elevated glucose-6-phosphate, derived from increased glucose uptake, also allosterically activates GYS1, reinforcing the glycogenic response. Thus, GYG2 acts downstream of insulin and upstream of GYS1, serving as a critical node that couples hormonal signals to glycogen accumulation.
In HeLa cancer cells, GYG2 knockout provides a powerful model to dissect the contribution of glycogenin-2-dependent glycogen synthesis to metabolic adaptation, including glycogen storage and utilization under varying nutrient conditions. Loss of GYG2 may impair glycogen accumulation, potentially affecting cell proliferation, redox balance, and survival during nutrient deprivation. This model enables detailed investigation of how glycogen metabolism intersects with insulin signaling and the PI3K/AKT pathway in cervical adenocarcinoma, shedding light on metabolic vulnerabilities that could be exploited therapeutically. Moreover, it allows assessment of altered sensitivity to chemotherapeutic agents, given the emerging role of glycogen in cancer cell stress resistance.
Typical applications include Western blotting and RT-qPCR for knockout validation, PAS staining to quantify glycogen content, immunofluorescence for subcellular localization studies, and metabolic flux analysis to trace glucose utilization. The polyclonal population supports drug target validation for glycogen storage diseases, diabetes mellitus, and metabolic syndrome, as well as investigation of cancer metabolic reprogramming. Researchers can employ flow cytometry to analyze cell cycle perturbations and glucose uptake assays to measure metabolic rewiring. These cells are also suitable for functional rescue experiments, genetic screens, and high-throughput compound testing. For technical inquiries or custom services, contact Ascent Research.
